A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group protocol 30867

Eur J Cancer Clin Oncol. 1989 Feb;25(2):389-90. doi: 10.1016/0277-5379(89)90035-7.
No abstract available

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Transitional Cell / drug therapy*
  • Drug Evaluation
  • Epirubicin / adverse effects
  • Epirubicin / therapeutic use*
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Male
  • Middle Aged
  • Nausea / chemically induced
  • Thrombocytopenia / chemically induced
  • Urinary Bladder Neoplasms / drug therapy*

Substances

  • Epirubicin